Genentech Presents Positive Data from Trials on Crenezumab and Gantenerumab for Alzheimer’s

Genentech Presents Positive Data from Trials on Crenezumab and Gantenerumab for Alzheimer’s
The latest clinical data from Genentech on crenezumab and gantenerumab demonstrate the investigational therapies’ potential to reduce amyloid aggregates in Alzheimer’s disease patients. Trial results were discussed in several presentations at the 2018 Alzheimer’s Association International Conference (AAIC), recently held in Chicago. “The range of data that Roche and Genentech are presenting at AAIC is

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. DANTE MARCIANI says:

    What are the effects on the cognitive functions of those receiving these antibodies? Can they compare with aducanumab and BAN2401 effects on cognitive functions? Plaque reduction is meaningless without an improvement of cognitive functions. Moreover, all of the failed antibodies and vaccines have reduced plaque without any benefits on the mental state of the patients.

Leave a Comment

Your email address will not be published. Required fields are marked *